One day in the thirteenth century, James I of Aragon, not only a great conqueror but a king famous for his powers of memory, made a revealing slip. Having convened an assembly of lords and clerics, he ...

Topline results from the OV329 Phase 1 safety, tolerability and biomarker study remain on track for a readout in Q3 2025 $7.0 million royalty monetization agreement signed with Immedica Pharma AB for ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell ...

Ovid Therapeutics (OVID) has drawn attention after reporting positive topline results from its Phase 1 study of OV329, a next-generation GABA-aminotransferase inhibitor that targets drug-resistant ...

Ovid Therapeutics (OVID) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to earnings of $0.12 per share a year ago. These ...

Who among lovers of literature and myth would want to do without the story of Mars and Venus and what they were doing when Vulcan imprisoned them in a net? Of Midas and the disastrous request he made ...

Esmé von Hoffman's reimagining of the ancient Roman poet as a Detroit lothario has plenty of ideas, but no clear audience in mind for them. Making the classics hip for a new generation is a ...

Topline pharmacodynamic biomarker, safety and tolerability results from a Phase 1 study of OV329 are on track to readout in Q3 2025 Ovid’s first program in its KCC2 direct activator library, OV350, ...